TrialThe Lancet. Neurology2019
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Ralf Reilmann et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
62 papers cite itlatest 60 shown
this paperpooled ittrialcites it